Related Experiment Video

Updated: Aug 11, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance

Su-Young Oh1, Ji-Hee Song, Jung-Eun Gil

  • 1Department of Human Genomics, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Taejeon 305-806, Korea.

Experimental Cell Research
|March 7, 2006
PubMed

Insights

Thymosin-beta-4 (TB4) overexpression increases paclitaxel resistance in cancer cells by elevating ERK phosphorylation. Inhibiting TB4 or ERK activity may overcome this resistance, offering new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Paclitaxel resistance is a major challenge in cancer therapy.
  • Thymosin-beta-4 (TB4) is implicated in tumor metastasis.
  • The role of TB4 in paclitaxel resistance is not fully understood.

Purpose of the Study:

  • To investigate the effect of TB4 overexpression on paclitaxel-induced cell death in HeLa cells.
  • To elucidate the molecular mechanisms underlying TB4-mediated paclitaxel resistance.

Main Methods:

  • Overexpression of TB4 in HeLa cells (TB4-HeLa).
  • Assessment of cell viability, apoptosis, and proliferation.
  • Analysis of ERK and p38 kinase phosphorylation.
  • Treatment with paclitaxel, TB4 siRNA, PD98059, and SB203580.

Main Results:

  • TB4-HeLa cells exhibited increased proliferation and resistance to paclitaxel-induced cell death compared to control HeLa cells.
  • TB4 overexpression led to elevated basal ERK phosphorylation and reduced basal p38 kinase phosphorylation.
  • Inhibition of basal ERK activity reversed paclitaxel resistance in TB4-HeLa cells.
  • Inhibition of p38 kinase attenuated paclitaxel-induced cell death in HeLa cells.

Conclusions:

  • TB4 induces paclitaxel resistance by increasing basal ERK phosphorylation.
  • TB4 represents a potential therapeutic target for overcoming paclitaxel resistance in cancer.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...